Print Page  Close Window


Overview

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$1.64
Change (%) Stock is Down 0.05 (2.96%)
Volume46,366
Nov 20, 2017 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
11/13/17Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin AmericaPrinter Friendly Version
11/13/17Orexigen Therapeutics Announces Third Quarter 2017 Financial ResultsPrinter Friendly Version
10/31/17Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13, 2017Printer Friendly Version
10/13/17Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.